SeeThruEquity Issues Update on Vitality Biopharma, Inc. (VBIO)

NEW YORK, NY / ACCESSWIRE / January 30, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update on Vitality Biopharma, Inc. and updated its target price to $3.00.

The report is available here: January 2018 Update Note.

Vitality Biopharma, Inc. (OTCQB: VBIO, “Vitality”). is focused on the development of cannabinoids for the treatment of serious neurological and inflammatory disorders. Vitality’s development pipeline is focused on a new class of cannabinoid prodrug pharmaceuticals called cannabosides. Cannabosides were discovered in 2015 through the application of the company’s proprietary enzymatic bioprocessing technologies, which were originally developed for stevia sweeteners. Cannabosides are cannabinoid glycoside “prodrugs,” which means they are medications or compounds that, after administration, are metabolized into a pharmacologically active drug. Vitality is developing cannaboside prodrugs for neurological diseases such as multiple sclerosis and inflammatory disorders, such as inflammatory bowel disease and narcotic bowel syndrome – a form of severe opiate-induced bowel dysfunction. Vitality’s lead candidates include VITA-100 for acute treatment of IBD and VITA-210, which is being investigated for chronic treatment of neuropathic pain, IBD, and muscle spasticity in multiple sclerosis.

Vitality Biopharma recently provided several investor updates with highlights including:

Vitality officially introduced VITA-100 as the company’s lead cannabinoid drug formulation. VITA-100 is a non-psychoactive, proprietary prodrug formulation of THC.

VITA-100 is a new cannabinoid prodrug called a cannaboside, which enables targeted delivery of THC to the large intestine.

THC has previously been approved by the FDA under the name dronabinol as a safe and effective means for appetite stimulation and to treat nausea.

Vitality previously announced encouraging pre-clinical data for VITA-100 showing reduced weight loss, decreased colon damage, and improved overall gastrointestinal health compared to placebo controls in a preclinical model of colitis.

The company plans to conduct its first-in-human studies in 1Q18, and is planning Phase 2 trials for inflammatory bowel syndrome (IBD), irritable bowel syndrome, and narcotic bowel syndrome – a severe form of opiate-induced pain.

These represent large market opportunities; there are approximately 1.6mn Americans living with the most common forms of IBD Crohn’s disease and colitis. Research firm Visiongain estimates the market for IBD at the company was $9.7 billion in 2017.

Vitality has applied for an Orphan Drug Designation for pediatric ulcerative colitis (UC), a chronic form of IBD which affects approximately 80,000 children in the US. If granted, would position the company for a more expedited and cost-efficient pathway for its first indication.

Increasing target to $3.00

We are updating the target to $3.00 following developmental progress made by the company including the introduction of VITA-100 for gut-targeted delivery of THC, as well as the application for an orphan drug designation for pediatric UC, which, if granted, could speed time to market and lower development costs. Upcoming catalysts include the initiation of Phase 2 human trials, which are expected to commence in 2Q18.

Please review important disclosures at www.seethruequity.com.

About Vitality Biopharma, Inc.

Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. www.vitality.bio.

About SeeThruEquity

Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.

For more information visit www.seethruequity.com.

Contact:

SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 487361